Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)
Fiche du document
2019
- handle: 10670/1.07yxob
- hal: hal-01992911
- doi: 10.1016/j.semarthrit.2018.07.005
- PII: S0049-0172(18)30262-2
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.semarthrit.2018.07.005
http://creativecommons.org/licenses/by-nc/ , info:eu-repo/semantics/OpenAccess
Mots-clés
Rheumatoid arthritis Patient perspective DMARDs (biologic) Spondyloarthritis Anti-TNF -bio]/Santé publique et épidémiologieSujets proches
Factors Agents, Manufacturers' Manufacturers' representatives FactorsCiter ce document
Marc Scherlinger et al., « Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4) », HAL-SHS : sociologie, ID : 10.1016/j.semarthrit.2018.07.005
Métriques
Partage / Export
Résumé
Objective : To study acceptance rate and factors influencing acceptance of the switch from originator etanercept (Enbrel©) to biosimilar etanercept (SB4, Bénépali©) in patients with rheumatic disease.Methods : Patients with a well-controlled rheumatic disease consulting in our rheumatology department were offered the switch for SB4. After oral and written information concerning biosimilar, free choice to accept the switch was left to the patients. The main outcome was primary switch acceptance rate defined by switch acceptance during the initial consult. Real switch adherence, socio-cultural factors and beliefs influencing switch acceptance rate were retrieved during a telephonic interview at distance from the consultation.Results : Fifty-two patients were eligible for the switch: 32 (62%) with spondyloarthritis and 20 (38%) with rheumatoid arthritis. The primary acceptance rate was 92% (48/52). Patients refusing the switch were more likely to report a bad opinion on generic drugs (100% vs 11%, p